@article {Alao2606, author = {Alao, John P. and Olesch, Jeanette and Sunnerhagen, Per}, title = {Inhibition of type I histone deacetylase increases resistance of checkpoint-deficient cells to genotoxic agents through mitotic delay}, volume = {8}, number = {9}, pages = {2606--2615}, year = {2009}, doi = {10.1158/1535-7163.MCT-09-0218}, publisher = {American Association for Cancer Research}, abstract = {Histone deacetylase (HDAC) inhibitors potently inhibit tumor growth and are currently being evaluated for their efficacy as chemosensitizers and radiosensitizers. This efficacy is likely to be limited by the fact that HDAC inhibitors also induce cell cycle arrest. Deletion of the class I HDAC Rpd3 has been shown to specifically suppress the sensitivity of Saccharomyces cerevisiae DNA damage checkpoint mutants to UV and hydroxyurea. We show that in the fission yeast Schizosaccharomyces pombe, inhibition of the homologous class I HDAC specifically suppresses the DNA damage sensitivity of checkpoint mutants. Importantly, the prototype HDAC inhibitor Trichostatin A also suppressed the sensitivity of DNA damage checkpoint but not of DNA repair mutants to UV and HU. TSA suppressed DNA damage activity independently of the mitogen-activated protein kinase{\textendash}dependent and spindle checkpoint pathways. We show that TSA delays progression into mitosis and propose that this is the main mechanism for suppression of the DNA damage sensitivity of S. pombe checkpoint mutants, partially compensating for the loss of the G2 checkpoint pathway. Our studies also show that the ability of HDAC inhibitors to suppress DNA damage sensitivity is not species specific. Class I HDACs are the major target of HDAC inhibitors and cancer cells are often defective in checkpoint activation. Effective use of these agents as chemosensitizers and radiosensitizers may require specific treatment schedules that circumvent their inhibition of cell cycle progression. [Mol Cancer Ther 2009;8(9):2606{\textendash}15]{\textcopyright} 2009 American Association for Cancer Research.}, issn = {1535-7163}, URL = {https://mct.aacrjournals.org/content/8/9/2606}, eprint = {https://mct.aacrjournals.org/content/8/9/2606.full.pdf}, journal = {Molecular Cancer Therapeutics} }